Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-10
2005-05-10
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S461000
Reexamination Certificate
active
06890917
ABSTRACT:
A geldanamycin derivative exhibiting significant preliminary in vivo activity, particularly significant oral in vivo activity, and a method of treating or preventing cancer in a host comprising administering a geldanamycin derivative to a host in an amount sufficient to treat or prevent cancer.
REFERENCES:
patent: 4261989 (1981-04-01), Sasaki et al.
patent: 5658756 (1997-08-01), Rodan et al.
patent: 5866397 (1999-02-01), Rodan et al.
patent: 5932566 (1999-08-01), Schnur et al.
patent: 5948814 (1999-09-01), Hwang et al.
patent: 5952175 (1999-09-01), Yue et al.
patent: 5958892 (1999-09-01), Mukhopadhyay et al.
patent: 5968921 (1999-10-01), Gold
patent: 6015659 (2000-01-01), Welch et al.
patent: 55111419 (1980-08-01), None
patent: 55111469 (1980-08-01), None
patent: 55111470 (1980-08-01), None
patent: WO 9501342 (1995-01-01), None
Sasaki et al., “Growth Inhibition of Virus Transformed Cells In Vitro and Antitumor Activity In Vivo of Geldanamycin and Its Derivatives,”Journal of Antibiotics, 1979, pp. 849-851, 32(8).
An et al., “Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity,”Cancer Chemother. Pharm. (1997), 60-64, 40.
Kelland et al., “DT-Diaphorase Expression and Tumor Cell Sensitivity to 17-Allylamino, 17-demethoxygeldanamycin, an Inhibitor of Heat Shock Protein 90,”Nat. Cancer Inst. (1999), 1940-1949, 91.
Kuduk et al., “Synthesis and Evaluation of Geldanamycin-Estradiol Hybrids,”J. Biorg. Med. Chem. Lett. (1999), 1233-1238, 9.
Kuduk et al., “Synthesis and Evaluation of Geldanamycin-Testosterone Hybrids,”J. Biorg. Chem. Lett. (2000), 1303-1306, 10.
Mandler et al., “Synthesis and Evaluation of Antiproliferative Activity of a Geldanamycin-Herceptin™ Immunoconjugate,”J. Biorg. Chem. Lett. (2000), 1025-1028, 10.
Neckers et al., “Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity,”Investigational New Drugs(1999), 361-373, 17.
Schnur et al., “Inhibition of the Oncogene Product p185erbB-2in Vitro and in Vivo by Geldanamycin and Dihydrogeldanamycin Derivatives,”J. Med. Chem. (1995), 3806-3812, 38.
Schnur et al., “erbB-2 Oncogene Inhibition by Geldanamycin Derivatives: Synthesis, Mechanism of Action, and Structure—Activity Relationships,”J. Med. Chem. (1995), 3813-3820, 38.
Webb et al., “The Geldanamycins Are Potent Inhibitors of the Hepatocyte Growth Factor/Scatter Factor-Met-Urokinase Plasminogen Activator-Plasmin Proteolytic Network,”Cancer Res. (2000), 342-349, 60.
Hollingshead Melinda G.
Sausville Edward A.
Snader Kenneth M.
Vishnuvajjala B. Rao
Kifle Bruck
Leydig , Voit & Mayer, Ltd.
The United States of America as represented by the Department of
LandOfFree
Geldanamycin derivative and method of treating cancer using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Geldanamycin derivative and method of treating cancer using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Geldanamycin derivative and method of treating cancer using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3383141